Loading
IARC estimates 24,499 new cancer cases and 17,213 cancer deaths in Nepal in 2024; the commonest new cancers are stomach, oesophagus and breast. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Nepal's incidence estimate is 5: rates based on incidence estimates or registry data from neighbouring countries. Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Stomach | 3,159 | 11.8 | Gastric & gastro-oesophageal junction cancer |
| Oesophagus | 2,069 | 7.8 | Oesophageal cancer |
| Breast | 1,746 | 11.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Liver and intrahepatic bile ducts | 1,623 | 6.1 | Hepatocellular carcinoma |
| Cervix uteri | 1,532 | 10.3 | Cervical cancer |
| Trachea, bronchus and lung | 1,477 | 5.5 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Lip, oral cavity | 1,369 | 5.1 | |
| Colorectum | 1,242 | 4.6 | Colorectal cancer |
| Gallbladder | 1,073 | 4.0 | Gallbladder cancer |
| Ovary | 904 | 5.9 | Ovarian cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Stomach | 2,690 | 10.1 | Gastric & gastro-oesophageal junction cancer |
| Oesophagus | 1,898 | 7.2 | Oesophageal cancer |
| Liver and intrahepatic bile ducts | 1,504 | 5.6 | Hepatocellular carcinoma |
| Trachea, bronchus and lung | 1,358 | 5.1 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Gallbladder | 884 | 3.3 | Gallbladder cancer |
| Cervix uteri | 879 | 6.0 | Cervical cancer |
| Lip, oral cavity | 843 | 3.2 | |
| Colorectum | 775 | 2.9 | Colorectal cancer |
| Breast | 750 | 5.0 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Ovary | 589 | 4.0 | Ovarian cancer |
No trial record in OnCo lists a site in Nepal. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Nepal.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Nepal is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
A deep dive for Nepal is ranked 43 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.